Skip to main content
. 2024 Mar 4;14:5365. doi: 10.1038/s41598-024-55320-1

Figure 1.

Figure 1

Study profile and participant disposition. Enrollment and follow-up of study participants vaccinated with 40 μg PTX-COVID19-B or 30 µg BNT162b2 after the first and second dose administration. EIP evaluable immunogenicity population, mITT modified Intent-to-Treat population, n number of participants.